Advancing antibody medicines that matter
AbCellera (trianni.com) scores 74 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, Technology brands, in the 37th percentile of 12584 Healthcare brands.
AbCellera is a Vancouver, Canada-based biotechnology company founded in 2012 that develops antibody-based medicines. It combines biology, computation, and engineering into an integrated technology platform to discover and develop differentiated antibody drug programs with first-in-class and best-in-class potential. The company works across multiple indications and modalities, supporting both its own pipeline and partner programs for pharmaceutical and biotech companies, aiming to bring innovative therapies to patients with unmet medical needs.
| Brand Name | AbCellera |
|---|---|
| Domain | trianni.com |
| Industry | Healthcare, Technology |
| Founded | 2012 |
| Headquarters | Vancouver |
| Main Competitors | Adimab (76/100), Absci (81/100), Twist Bioscience (80/100), Generate Biomedicines (73/100), Ligand Pharmaceuticals (OmniAb) (82/100), WuXi Biologics (63/100) |
Moz Domain Authority 25/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We are advancing differentiated antibody drug programs with first-in-class and best-in-class potential across multiple indications and modalities." (Meta description: 17 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare.
Social footprint: verified profiles on LinkedIn, X (Twitter), Facebook, Instagram, GitHub; no detected presence on YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
AbCellera's main competitors in Healthcare: Adimab (76/100), Absci (81/100), Twist Bioscience (80/100), Generate Biomedicines (73/100), Ligand Pharmaceuticals (OmniAb) (82/100).
Sources: Brand Analyzer scan
AbCellera has limited AI-search visibility, scoring 26/100 on Brand Analyzer's AI visibility composite (visibility 23, trust 22, recommendation 37). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: AbCellera official site
AbCellera was founded in 2012. AbCellera operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
AbCellera is headquartered in Vancouver. AbCellera operates in the Healthcare category.
Sources: Wikidata
AbCellera discovers and develops differentiated antibody drug programs with first-in-class and best-in-class potential. It uses an integrated platform combining biology, computation, and engineering to accelerate antibody discovery and development from target identification to clinical stages, working both on its own pipeline and in partnership with pharmaceutical and biotech companies.
Sources: AbCellera official site
AbCellera scores 37/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: AbCellera official site
AbCellera is a technology-driven biotechnology company headquartered in Vancouver, Canada, founded in 2012. It focuses on discovering and developing antibody-based medicines, integrating biology, computation, and engineering into a single platform used for both its own drug pipeline and partner programs.
Sources: AbCellera official site
AbCellera can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: AbCellera official site
AbCellera offers an antibody discovery and development platform that combines biology, computation, and engineering. This platform supports the creation of antibody drug programs with first-in-class and best-in-class potential, serving both its own pipeline and partnered programs with pharmaceutical and biotech companies.
Sources: AbCellera official site
AbCellera is known for its integrated technology platform that merges biology, computational tools, and engineering to speed up the discovery and development of antibody-based therapeutics, supporting both proprietary and partnered drug programs across multiple disease indications.
Sources: AbCellera official site
AbCellera's platform and services are used by pharmaceutical and biotech partners seeking to discover and develop antibody-based medicines. Investors and, ultimately, patients needing innovative treatments for unmet medical needs are also part of its broader target audience.
Sources: AbCellera official site
AbCellera scores 26/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
AbCellera has a weak AI-visibility profile at 26/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (37/100) and its weakest is trust (22/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 25/100 and thin schema.org structured data.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to AbCellera: Tri-anim (74/100), Treloar's (74/100), Trillium Health Partners (74/100), TripleBlind (74/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.